Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb;9 Suppl 1(0 1):S1-29.
doi: 10.6004/jnccn.2011.0124.

NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy

Gary R Hudes, Michael A Carducci, Toni K Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A Margolin, M Dror Michaelson, Robert J Motzer, Roberto Pili, Susan Roethke, Sandy Srinivas

NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy

Gary R Hudes et al. J Natl Compr Canc Netw. 2011 Feb.

Abstract

The outcome of patients with metastatic renal cell carcinoma has been substantially improved with administration of the currently available molecularly targeted therapies. However, proper selection of therapy and management of toxicities remain challenging. NCCN convened a multidisciplinary task force panel to address the clinical issues associated with these therapies in attempt to help practicing oncologists optimize patient outcomes. This report summarizes the background data presented at the task force meeting and the ensuing discussion.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Therapeutic targets in renal cell carcinoma. Abbreviations: HIF, hypoxia-induced factor; mTORC1/2, mammalian target of rapamycin complexes 1 and 2; PDK1, phosphoinositide-dependant kinase-1; PI3K, phosphatidylinositol 3-kinase; RCC, renal cell carcinoma; RTKs, receptor tyrosine kinase; VEGF, vascular endothelial growth factor; VHL, von Hippel-Lindau. Modified from Courtney KD, Choueiri TK. Optimizing recent advances in metastatic renal cell carcinoma. Curr Oncol Rep 2009;11:218–226; with kind permission from Springer Science+Business Media.
Figure 2
Figure 2
Hand and foot syndrome reaction.
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. - PubMed
    1. Motzer RJ, Agarwal N, Beard C, et al. [Accessed January 5, 2011];NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer, version 1.2011. Available at: www.NCCN.org/professionals/physician_gls/PDF/kidney.pdf.
    1. Brannon AR, Reddy A, Seiler M, et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer. 2010;1:152–163. - PMC - PubMed
    1. Eble J, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004.
    1. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49:798–805. - PubMed

MeSH terms